US 9,808,367 B2
Methods, devices, and systems for obesity treatment
Richard D. Y. Chen, Napa, CA (US); Craig A. Johanson, San Francisco, CA (US); Christopher S. Jones, Menlo Park, CA (US); Reinhold H. Dauskardt, Menlo Park, CA (US); and Mark B. Taub, Mountain View, CA (US)
Assigned to Fulfillium, Inc., Napa, CA (US)
Filed by Fulfillium, Inc., Napa, CA (US)
Filed on Jun. 13, 2017, as Appl. No. 15/621,795.
Application 15/621,795 is a continuation of application No. 15/232,485, filed on Aug. 9, 2016.
Application 15/232,485 is a continuation of application No. 14/971,845, filed on Dec. 16, 2015, granted, now 9,456,915.
Application 14/971,845 is a continuation of application No. 11/282,224, filed on Nov. 18, 2005, abandoned.
Application 11/282,224 is a continuation in part of application No. 11/170,274, filed on Jun. 28, 2005, granted, now 8,070,807.
Application 11/170,274 is a continuation in part of application No. 11/122,315, filed on May 3, 2005, granted, now 8,066,780.
Application 11/170,274 is a continuation in part of application No. 15/621,795, filed on Jun. 13, 2017.
Application 15/621,795 is a continuation of application No. 15/231,167, filed on Aug. 8, 2016.
Application 15/231,167 is a continuation of application No. 14/971,795, filed on Dec. 16, 2015, granted, now 9,445,930.
Application 14/971,795 is a continuation of application No. 11/282,224.
Application 11/282,224 is a continuation in part of application No. 11/170,274.
Application 11/170,274 is a continuation in part of application No. 11/122,315.
Claims priority of provisional application 60/629,800, filed on Nov. 19, 2004.
Prior Publication US 2017/0273813 A1, Sep. 28, 2017
This patent is subject to a terminal disclaimer.
Int. Cl. A61F 2/04 (2013.01); A61M 29/02 (2006.01); A61F 5/00 (2006.01)
CPC A61F 5/0033 (2013.01) [A61F 5/0036 (2013.01); A61F 2250/0002 (2013.01); A61F 2250/008 (2013.01)] 23 Claims
OG exemplary drawing
 
16. An obesity treatment system for deployment in a stomach of a patient such that the system is free-floating and untethered after deployment, comprising:
a plurality of adjacent, non-concentric, spaced apart inflatable space-filling compartments, wherein each compartment of the plurality of inflatable space-filling compartments has a respective inflated state volume during treatment of the patient; and
at least two valves to introduce at least one fluid into each of the plurality of inflatable space-filling compartments and to retain, after inflation, fluid in the plurality of inflatable space-filling compartments, wherein each valve is a one-way valve and wherein at least one of the at least two valves has a proximal end configured to removably attach to an inflation tube;
wherein the plurality of inflatable space-filling compartments form, upon at least partially filling the plurality of inflatable space-filling compartments, a dual balloon system that is configured to float within the stomach;
wherein the dual-balloon system is configured to float freely in the patient's stomach and is not connected to any catheter, lumen or tether after deployment in the patient's stomach;
wherein, upon inflation, the dual balloon system is configured to float within the stomach without exerting pressure at any point in the stomach sufficient to cause abrasion, pressure induced lesions, or other trauma.